Based on the key indicators related to EXACT Sciences' liquidity, profitability, solvency, and operating efficiency, EXACT Sciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August. At this time, EXACT Sciences' Other Stockholder Equity is comparatively stable compared to the past year. Total Liabilities is likely to gain to about 3.7 B in 2025, whereas Accumulated Other Comprehensive Income is likely to drop (991.2 K) in 2025. Key indicators impacting EXACT Sciences' financial strength include:
Investors should never underestimate EXACT Sciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor EXACT Sciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in EXACT Sciences.
Understanding current and past EXACT Sciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of EXACT Sciences' financial statements are interrelated, with each one affecting the others. For example, an increase in EXACT Sciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in EXACT Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of EXACT Sciences. Check EXACT Sciences' Beneish M Score to see the likelihood of EXACT Sciences' management manipulating its earnings.
EXACT Sciences Stock Summary
EXACT Sciences competes with Guardant Health, Illumina, Twist Bioscience, Natera, and Pacific Biosciences. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 6420 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what EXACT Sciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining EXACT Sciences's current stock value. Our valuation model uses many indicators to compare EXACT Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EXACT Sciences competition to find correlations between indicators driving EXACT Sciences's intrinsic value. More Info.
EXACT Sciences is rated # 4 in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . At this time, EXACT Sciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value EXACT Sciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
EXACT Sciences Systematic Risk
EXACT Sciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. EXACT Sciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on EXACT Sciences correlated with the market. If Beta is less than 0 EXACT Sciences generally moves in the opposite direction as compared to the market. If EXACT Sciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one EXACT Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of EXACT Sciences is generally in the same direction as the market. If Beta > 1 EXACT Sciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in EXACT Sciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various EXACT Sciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of EXACT Sciences growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of EXACT Sciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of EXACT Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of EXACT Sciences based on widely used predictive technical indicators. In general, we focus on analyzing EXACT Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build EXACT Sciences's daily price indicators and compare them against related drivers.
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.